Aktieanalys

Moberg Pharma Q3’23: National approvals as expected - Redeye

Redeye 07 Nov 2023 09:37

Redeye saw a report that came in more or less as expected. There were as expected no sales in the quarter and costs were more or less in our expectations. The main events in the quarter are the national approvals in another ten countries. However, this was expected as the recommendation in the EU was strong. The approvals are positive as they prove that the process is going forward and that there seem to be no real issues. More approvals will come in the coming quarters. The most important national approvals in the short term are Sweden and Norway, as these are the countries where sales could start in the first half of 2024e.

Länk till analysen i sin helhet: https://www.redeye.se/research/955942/moberg-pharma-q323-national-approvals-as-expected?utm_source=finwire&utm_medium=RSS

Börskollens app – Högt betyg ⭐⭐⭐⭐⭐ och 250.000 nedladdningar

Ladda hem

Vårt nyhetsbrev – Utvalda börsnyheter och heta investeringscase varje vecka

Prenumerera

Nyheter om Moberg Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!